NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that on August 29, 2007 it received a letter from The NASDAQ Stock Market stating that AVANT was approved to list its common stock on The NASDAQ Capital Market. AVANT’s common stock will be transferred to The NASDAQ Capital Market from The NASDAQ Global Market at the opening of business on August 31, 2007.
